Molecular docking analysis of imiquimod with the TGF-β targets for oral carcinoma.

Jayanthi Pazhani, Vishnu Priya Veeraraghavan, Selvaraj Jayaraman

Open access · hybridAbstract read

In one paragraph

Article in Bioinformation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 40% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jayanthi PazhaniCentre of Molecular Medicine and Diagnostics (COMManD), Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai-600077, India.

Vishnu Priya VeeraraghavanCentre of Molecular Medicine and Diagnostics (COMManD), Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai-600077, India.

Selvaraj JayaramanCentre of Molecular Medicine and Diagnostics (COMManD), Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai-600077, India.

Saveetha University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TGF-βsignalling pathway is the main signalling pathways that regulate various biological functions such as cell proliferation, apoptosis, metabolic dysregulation, and metastasis in many cancer cells. Previous studies have elaborated the role of TGF-βsignalling targets have a significant regulatory function in various cancers. Moreover targeting the epithelial to mesenchymal transition markers in oral squamous cell carcinoma not yet elucidated. Therefore, it is of interest to document the molecular docking analysis of TGF-βsignalling pathway targets such as Smad2, GATA2 and MAFG with imiquimod. These results suggest that targeting the TGF-βsignaling pathway downstream targets with imiquimod might leads to an improved outcome as potential therapeutic options in oral carcinoma.

Indexed as

Imiquimodmolecular dockingOral cancerTGF-β signaling

Identifiers

PMID37822834

DOI10.6026/97320630019467

PMCPMC10563569

OpenAlexW4387563565

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.